John Liles

Drug discovery biologist and leader with proven success advancing novel therapeutics from target validation through Phase 3 development • Executive leadership team, small molecule and siRNA pipeline and research strategy • Lead Research groups responsible for target discovery/validation, translational data, non-clinical development, strategic collaborations and partnerships; and cross-functional teams dedicated to target discovery and pipeline expansion • Accomplished team builder and project team leader that has successfully advanced internal and external programs into clinical development across several indications (DKD, PAH/cardiovascular, NASH, PSC/PBC). • Extensive experience identifying external opportunities for pipeline expansion, and leading cross-functional diligence evaluations • Deep expertise leading in vitro/in vivo pharmacology teams to drive program decisions • Oversee external partnerships to expand pipeline and validate therapeutic targets and novel platforms • Strong track record of establishing engaged and productive CRO and KOL networks to efficiently advance programs for inflammation, metabolic, renal, CV, and liver indications